Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020)
Boston Scientific's (BSX) quarterly Current Deferred Revenue came in at $258.0 million in Q3 2020, up 2.79% quarter-over-quarter from $251.0 million in Q2 2020.
Powered by 
Analysis
Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Boston Scientific has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $258.0 million for Q3 2020.
- In Q3 2020, Current Deferred Revenue changed N/A year-over-year to $258.0 million; the TTM figure through Sep 2020 stood at $258.0 million (changed N/A YoY), while the FY2019 annual figure was $257.0 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $258.0 million for Q3 2020 at Boston Scientific, up from $251.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $258.0 million in Q3 2020 to a low of $251.0 million in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Zimmer Biomet Holdings | 18.20 Bn | 17.79 Bn | 1.54 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 258.00 Mn |
| Jun 30, 2020 | 251.00 Mn |
| Mar 31, 2020 | 251.00 Mn |
| Dec 31, 2019 | 257.00 Mn |